Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate how well tolerated and effective an angiotensin
receptor-neprilysin inhibitor (sacubitril-valsartan) is in patients with contemporary durable
continuous flow left ventricular assist device (CF-LVAD) implantation compared to usual care
oral vasodilator therapy.
Phase:
Phase 4
Details
Lead Sponsor:
The Cleveland Clinic
Treatments:
LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan Vasodilator Agents